Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing

[1]  I. Turnbull,et al.  Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases , 2022, Cells.

[2]  M. Dickinson,et al.  AAV5 delivery of CRISPR/Cas9 supports effective genome editing in mouse lung airway. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  James E. Dahlman,et al.  Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs , 2021, Nature Biomedical Engineering.

[4]  V. Gradinaru,et al.  Deep Parallel Characterization of AAV Tropism and AAV-Mediated Transcriptional Changes via Single-Cell RNA Sequencing , 2021, bioRxiv.

[5]  Mary E. Haas,et al.  Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 , 2021, Proceedings of the National Academy of Sciences.

[6]  J. Knight,et al.  Host genetics and infectious disease: new tools, insights and translational opportunities , 2020, Nature Reviews Genetics.

[7]  James E. Dahlman,et al.  Treating cystic fibrosis with mRNA and CRISPR. , 2020, Human gene therapy.

[8]  Fathema Uddin,et al.  CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future , 2020, Frontiers in Oncology.

[9]  Luis A. Barrera,et al.  Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing , 2020, Science Advances.

[10]  Daniel G. Anderson,et al.  Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver , 2020, Nature Communications.

[11]  Y. Ping,et al.  Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders. , 2020, Advanced drug delivery reviews.

[12]  B. Soh,et al.  Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing , 2020, Journal of Molecular Medicine.

[13]  Qiang Cheng,et al.  Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing , 2020, Nature Nanotechnology.

[14]  Jennifer A. Doudna,et al.  THE PROMISE AND CHALLENGE OF THERAPEUTIC GENOME EDITING , 2020, Nature.

[15]  S. Randell,et al.  Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis , 2019, Front. Pharmacol..

[16]  Robert Langer,et al.  Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium , 2019, Advanced materials.

[17]  Y. Suh,et al.  In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease , 2017, F1000Research.

[18]  Robert Langer,et al.  Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse , 2017, Molecular therapy. Nucleic acids.

[19]  Daniel G. Anderson,et al.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.

[20]  Hao Yin,et al.  Delivery technologies for genome editing , 2017, Nature Reviews Drug Discovery.

[21]  Anirvan Ghosh,et al.  Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes , 2017, Nature Biotechnology.

[22]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[23]  Daniel G. Anderson,et al.  Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. , 2015, Nano letters.

[24]  Feng Zhang,et al.  In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 , 2014, Nature Biotechnology.

[25]  Elizabeth A. Calle,et al.  Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. , 2014, Cell stem cell.

[26]  E. Morrisey,et al.  Lung regeneration: mechanisms, applications and emerging stem cell populations , 2014, Nature Medicine.

[27]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[28]  E. Morrisey,et al.  Lung development: orchestrating the generation and regeneration of a complex organ , 2014, Development.

[29]  K. G. Rajeev,et al.  Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[31]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[32]  B. Thébaud.  Angiogenesis in Lung Development, Injury and Repair: Implications for Chronic Lung Disease of Prematurity , 2007, Neonatology.

[33]  D. Rudnick,et al.  CONCISE REVIEW IN MECHANISMS OF DISEASE Alpha-1-Antitrypsin Deficiency: A New Paradigm for Hepatocellular Carcinoma in Genetic Liver Disease , 2005 .

[34]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.